When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Anti-VEGF - Wikipedia

   en.wikipedia.org/wiki/Anti-VEGF

   By May 2012, anti-VEGF treatment with Avastin has been accepted by Medicare, is quite reasonably priced, and effective. Lucentis has a similar but smaller molecular structure to Avastin, and is FDA-approved (2006) for treating MacD, yet remains more costly, as is the more recent (approved in 2011) aflibercept (Eylea). Tests on these treatments ...

3. FDA Approves Biosimilars for Macular Degeneration Treatment - AOL

   www.aol.com/fda-approves-biosimilars-macular...

   The Food and Drug Administration approved two interchangeable biosimilars to Eylea (aflibercept), a brand name drug used to treat age-related macular degeneration, diabetic retinopathy and other ...

4. US FDA approves higher dose of Regeneron's eye disease drug Eylea

   www.aol.com/news/us-fda-approves-higher-dose...

   The drug, Eylea HD, is priced at $2,625 per single-use vial in the U.S. and is used to treat patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic ...

5. Aflibercept - Wikipedia

   en.wikipedia.org/wiki/Aflibercept

   Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. [16] [17] It was developed by Regeneron Pharmaceuticals.

6. Regeneron's Eylea could return to growth after nod to high ...

   www.aol.com/news/regenerons-eylea-could-return...

   The higher dose of the drug was approved for the same diseases as the previous version, wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. A longer dosing gap ...

7. Intravitreal administration - Wikipedia

   en.wikipedia.org/wiki/Intravitreal_administration

   One clinical trial of ranibizumab for age-related macular degeneration administered intravitreally reported intraocular inflammation rates between 1.4% and 2.9%. Bevacizumab, another medication for the same purpose, resulted in an incidence between 0.09% and 0.4%.